Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Barsh, G
Jathar VS, Hirwe R, Desai S, Satoskar RS
Incretin-based drug development As mentioned above, endogenous GLP-1 has a very short half-life (1-2 minutes) due to its rapid degradation by DPP4, limiting its utility for treatment as a therapeutic
The salivary glands of gila monsters produce a GLP-1 peptide that does not have a DPP-4-recognized site leading to the first therapeutic incretin, exenatide - a twice daily subcutaneous injection [25]
A comprehensive survey on the detection, classification, and challenges of neurological disorders
:max_bytes(150000):strip_icc()/VWH-GettyImages-1469751146-5eff6dd0b38449ff9dca9313c7c393d5.jpg)
US$ 28.93
US$ 28.04
US$ 29.01
.jpg?width=602&height=602&name=Final%20(2).jpg)
